119 related articles for article (PubMed ID: 37674722)
1. Recurrent oropharyngeal squamous cell carcinomas maintain anti-tumor immunity and multinucleation levels following completion of radiation.
Castro P; Corredor G; Koyuncu C; Nordstrom LA; Tiji M; Leavitt T; Lewis JS; Madabhushi A; Frederick MJ; Sandulache VC
Res Sq; 2023 Aug; ():. PubMed ID: 37674722
[TBL] [Abstract][Full Text] [Related]
2. Recurrent Oropharyngeal Squamous Cell Carcinomas Maintain Anti-tumor Immunity and Multinucleation Levels Following Completion of Radiation.
Castro P; Corredor G; Koyuncu C; Nordstrom LA; Tiji M; Leavitt T; Lewis JS; Madabhushi A; Frederick MJ; Sandulache VC
Head Neck Pathol; 2023 Dec; 17(4):952-960. PubMed ID: 37995073
[TBL] [Abstract][Full Text] [Related]
3. The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma.
Gurin D; Slavik M; Hermanova M; Selingerova I; Kazda T; Hendrych M; Shatokhina T; Vesela M
J Oral Pathol Med; 2020 Oct; 49(9):886-896. PubMed ID: 32516834
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
5. Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma.
Brcic I; Gallob M; Schwantzer G; Zrnc T; Weiland T; Thurnher D; Wolf A; Brcic L
Oral Oncol; 2020 Jul; 106():104719. PubMed ID: 32335324
[TBL] [Abstract][Full Text] [Related]
6. CD8+ T Cells and PD-L1 Expression as Prognostic Indicators in a Low Prevalence of HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
Atipas K; Laokulrath N; Petsuksiri J; Ratanaprasert N; Pongsapich W
Curr Oncol; 2023 Jan; 30(2):1450-1460. PubMed ID: 36826072
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8
Hladíková K; Koucký V; Bouček J; Laco J; Grega M; Hodek M; Zábrodský M; Vošmik M; Rozkošová K; Vošmiková H; Čelakovský P; Chrobok V; Ryška A; Špíšek R; Fialová A
J Immunother Cancer; 2019 Oct; 7(1):261. PubMed ID: 31623665
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma.
Wuerdemann N; Gültekin SE; Pütz K; Wittekindt C; Huebbers CU; Sharma SJ; Eckel H; Schubotz AB; Gattenlöhner S; Büttner R; Speel EJ; Klussmann JP; Wagner S; Quaas A
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718057
[TBL] [Abstract][Full Text] [Related]
9. Deployment of cisplatin in Veterans with oropharyngeal cancer: toxicity and impact on oncologic outcomes.
Soliman O; Wilde DC; Kemnade JO; Sabichi AL; Chen G; Chen A; Little SN; Huang AT; Hernandez DJ; Sandulache VC
Laryngoscope Investig Otolaryngol; 2023 Aug; 8(4):895-902. PubMed ID: 37621289
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment.
Sato F; Ono T; Kawahara A; Kawaguchi T; Tanaka H; Shimamatsu K; Kakuma T; Akiba J; Umeno H; Yano H
J Clin Pathol; 2019 Aug; 72(8):542-549. PubMed ID: 31113825
[TBL] [Abstract][Full Text] [Related]
11. Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma.
Fukushima Y; Someya M; Nakata K; Hori M; Kitagawa M; Hasegawa T; Tsuchiya T; Gocho T; Ikeda H; Hirohashi Y; Torigoe T; Sugita S; Hasegawa T; Himi T; Sakata KI
Radiother Oncol; 2018 Nov; 129(2):409-414. PubMed ID: 30249348
[TBL] [Abstract][Full Text] [Related]
12. Oropharyngeal cancer outcomes correlate with p16 status, multinucleation and immune infiltration.
Wilde DC; Castro PD; Bera K; Lai S; Madabhushi A; Corredor G; Koyuncu C; Lewis JS; Lu C; Frederick MJ; Frederick AM; Haugen AE; Zevallos JP; Sturgis EM; Shi J; Huang AT; Hernandez DJ; Skinner HD; Kemnade JO; Yu W; Sikora AG; Sandulache VC
Mod Pathol; 2022 Aug; 35(8):1045-1054. PubMed ID: 35184149
[TBL] [Abstract][Full Text] [Related]
13. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
[TBL] [Abstract][Full Text] [Related]
14. Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma.
Zhu Y; Zhu X; Diao W; Liang Z; Gao Z; Chen X
Clin Oral Investig; 2023 Apr; 27(4):1423-1433. PubMed ID: 36884083
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819
[TBL] [Abstract][Full Text] [Related]
16. Machine learning driven index of tumor multinucleation correlates with survival and suppressed anti-tumor immunity in head and neck squamous cell carcinoma patients.
Koyuncu CF; Frederick MJ; Thompson LDR; Corredor G; Khalighi S; Zhang Z; Song B; Lu C; Nag R; Sankar Viswanathan V; Gilkey M; Yang K; Koyfman SA; Chute DJ; Castro P; Lewis JS; Madabhushi A; Sandulache VC
Oral Oncol; 2023 Aug; 143():106459. PubMed ID: 37307602
[TBL] [Abstract][Full Text] [Related]
17. Computerized tumor multinucleation index (MuNI) is prognostic in p16+ oropharyngeal carcinoma.
Koyuncu CF; Lu C; Bera K; Zhang Z; Xu J; Toro P; Corredor G; Chute D; Fu P; Thorstad WL; Faraji F; Bishop JA; Mehrad M; Castro PD; Sikora AG; Thompson LD; Chernock RD; Lang Kuhs KA; Luo J; Sandulache V; Adelstein DJ; Koyfman S; Lewis JS; Madabhushi A
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651718
[TBL] [Abstract][Full Text] [Related]
18. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
19. Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma.
Howard J; Masterson L; Dwivedi RC; Riffat F; Benson R; Jefferies S; Jani P; Tysome JR; Nutting C
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD010963. PubMed ID: 27943254
[TBL] [Abstract][Full Text] [Related]
20. Tumor cell anaplasia and multinucleation are predictors of disease recurrence in oropharyngeal squamous cell carcinoma, including among just the human papillomavirus-related cancers.
Lewis JS; Scantlebury JB; Luo J; Thorstad WL
Am J Surg Pathol; 2012 Jul; 36(7):1036-46. PubMed ID: 22743286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
